INDOCYANINE GREEN FOR INJECTION, USP POWDER FOR SOLUTION

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

INDOCYANINE GREEN

Disponibbli minn:

DIAGNOSTIC GREEN LIMITED

Kodiċi ATC:

V04CX01

INN (Isem Internazzjonali):

INDOCYANINE GREEN

Dożaġġ:

25MG

Għamla farmaċewtika:

POWDER FOR SOLUTION

Kompożizzjoni:

INDOCYANINE GREEN 25MG

Rotta amministrattiva:

INTRAVENOUS

Unitajiet fil-pakkett:

15G/50G

Tip ta 'preskrizzjoni:

Ethical

Żona terapewtika:

CARDIAC FUNCTION

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0150962001; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2019-02-15

Karatteristiċi tal-prodott

_Indocyanine Green for Injection, USP Product Monograph _
_Page 1 of 14 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Indocyanine Green for Injection, USP
Lyophilized green powder containing 25 mg of indocyanine green,
Intravenous Injection
Diagnostic Agent
Imported and Distributed By:
Seaford Pharmaceuticals Inc.
28-1530 Drew Road
Mississauga Ontario
Canada L5S 1W8
Date of Initial Approval:
FEB 15, 2019
Date of Revision:
June 30, 2021
Marketing Authorization Holder:
Diagnostic Green GmbH
Otto-Hahn-Straße 20
85609 Aschheim-Dornach
Bavaria, Germany
Submission Control No: 248253
_Indocyanine Green for Injection, USP Product Monograph _
_Page 2 of 14 _
TABLE OF CONTENTS
TABLE OF CONTENTS
......................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION ...................................................... 3
1
INDICATIONS ..........................................................................................................
3
1.1
Pediatrics...........................................................................................................
3
1.2
Geriatrics...........................................................................................................
3
2
CONTRAINDICATIONS ..........................................................................................
3
3
DOSAGE AND ADMINISTRATION ........................................................................
3
3.1
Recommended Dose and Dosage Adjustment
..................................................... 3
3.1.1
Indicator-Dilution Studies
...............................................................................
3
3.1.2
Hepatic Function Studies
................................................................................
4
3.1.3
Ophthalmic Angiography
Studies....................................................................
7
4
OVERDOSAGE .....................................................................................................